EUVIMEDOpdag EUVIMED
Open access

New High-Throughput Screen Discovers Novel Ligands of Full-Length Nuclear Receptor LRH-1

M Merced Malabanan, Pratima Chapagain, Zeinab Haratipour, Woong Jae Choi, Abigail R Orun iD, Raymond D Blind iD

ACS Chemical Biology · 2023-05-19 · 18 (5) · 1101-1114

DOI: 10.1021/acschembio.2c00805 ↗

At a glance

Journal article in ACS Chemical Biology, published online on 2023-04-19. Written by M Merced Malabanan and 5 co-authors. Institution: Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United …. Major MEDLINE topics: Gene Expression Regulation, Receptors, Cytoplasmic and Nuclear. Cited 9 times so far (Crossref); 71 references. The full text is freely available in PubMed Central. Funded by: NIDDK NIH HHS, NHGRI NIH HHS, NIGMS NIH HHS.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Nuclear receptor liver receptor homolog-1 (LRH-1, NR5A2) is a lipid-regulated transcription factor and an important drug target for several liver diseases. Advances toward LRH-1 therapeutics have been driven recently by structural biology, with fewer contributions from compound screening. Standard LRH-1 screens detect compound-induced interaction between LRH-1 and a transcriptional coregulator peptide, an approach that excludes compounds that regulate LRH-1 through alternative mechanisms. Here, we developed a FRET-based LRH-1 screen that simply detects compound binding to LRH-1, applying it to discover 58 new compounds that bind the canonical ligand-binding site in LRH-1 (2.5% hit rate), also supported by computational docking. Four independent functional screens identified 15 of these 58 compounds to also regulate LRH-1 function in vitro or in living cells. Although one of these 15 compounds, abamectin, directly binds LRH-1 and regulates full-length LRH-1 in cells, abamectin failed to regulate the isolated ligand-binding domain in standard coregulator peptide recruitment assays using PGC1α, DAX-1, or SHP. Abamectin treatment of human liver HepG2 cells selectively regulated endogenous LRH-1 ChIP-seq target genes and pathways associated with known LRH-1 functions in bile acid and cholesterol metabolism. Thus, the screen reported here can discover compounds not likely to have been identified in standard LRH-1 compound screens but which bind and regulate full-length LRH-1 in cells.

Subjects

MeSH terms (MEDLINE)

Gene Expression RegulationReceptors, Cytoplasmic and NuclearHumansLigandsTranscription FactorsIvermectin

Substances

LigandsReceptors, Cytoplasmic and NuclearTranscription FactorsabamectinIvermectinNR5A2 protein, human

Authors and institutions

  • Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States.
  • Department of Biochemistry and Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States.

ORCID profiles: Abigail R Orun, Raymond D Blind

Funding

  • NIDDK NIH HHS
  • NHGRI NIH HHS
  • NIGMS NIH HHS
  • NCI NIH HHS
  • Vanderbilt University
  • National Human Genome Research Institute
  • American Cancer Society
  • National Institutes of Health

Cite

APA

Malabanan, M. M., Chapagain, P., Haratipour, Z., Choi, W. J., Orun, A. R., & Blind, R. D. (2023). New High-Throughput Screen Discovers Novel Ligands of Full-Length Nuclear Receptor LRH-1. ACS Chemical Biology, 18(5), 1101-1114. https://doi.org/10.1021/acschembio.2c00805

Vancouver

Malabanan MM, Chapagain P, Haratipour Z, Choi WJ, Orun AR, Blind RD. New High-Throughput Screen Discovers Novel Ligands of Full-Length Nuclear Receptor LRH-1. ACS Chemical Biology. 2023;18(5):1101-1114. doi:10.1021/acschembio.2c00805

BibTeX
@article{Malabanan2023,
  author = {Malabanan, M Merced and Chapagain, Pratima and Haratipour, Zeinab and Choi, Woong Jae and Orun, Abigail R and Blind, Raymond D},
  title = {New High-Throughput Screen Discovers Novel Ligands of Full-Length Nuclear Receptor LRH-1},
  journal = {ACS Chemical Biology},
  year = {2023},
  volume = {18},
  number = {5},
  pages = {1101--1114},
  doi = {10.1021/acschembio.2c00805}
}
Start for free →